How Can Blockchain Be Implemented In The Pharmaceutical Industry?

November 15, 2019

Blockchain owns its reputation by providing many valuable advantages for everyday business and more complex operations. In this article, we want to disclose how the technology could be and already is implemented in the pharmaceutical industry. Moreover, we will discuss track and trace potential in this topic.

Spotlight

Enobia Pharma

Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product in development, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted enzyme replacement therapy for the rare disease hyposphostasia.

OTHER VIDEOS

Welcome to the Azelis Pharma lab in Paris, France!

video | January 30, 2023

As a leading global innovation service provider in the specialty chemicals and food ingredients industry, we are committed to creating value for principals and customers whilst providing a great work environment and career opportunities....

Watch Now

Daikyo Crystal Zenith® Insert Needle Syringe

video | January 27, 2023

The Daikyo Crystal Zenith® Insert Needle Syringe system was designed to maintain purity, integrity and efficacy of premium biopharmaceutical therapies....

Watch Now

Little Green Pharma continues to expand making significant strides

video | January 31, 2023

Leading Australian medicinal cannabis exporter, Little Green Pharma continues to expand making significant strides in lucrative global markets...

Watch Now

Teva Expands Partnership to Bring Critical Medicines to Children Living with Cancer

video | January 26, 2023

Teva believes medicine should always be accessible, and we work to help make this a reality. We're working with Global HOPE (Hematology Oncology Pediatric Excellence), a non-profit...

Watch Now

Spotlight

Enobia Pharma

Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product in development, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted enzyme replacement therapy for the rare disease hyposphostasia.

Events